Literature DB >> 23670192

An essential role of antibodies in the control of Chikungunya virus infection.

Fok-Moon Lum1, Teck-Hui Teo, Wendy W L Lee, Yiu-Wing Kam, Laurent Rénia, Lisa F P Ng.   

Abstract

In recent years, Chikungunya virus (CHIKV) was responsible for epidemic outbreaks in intertropical regions. Although acquired immunity has been shown to be crucial during CHIKV infection in both humans and mice, their exact role in the control of CHIKV infection remains unclear. In this study, wild-type (WT), CD4(-/-), and B cell (μMT) knockout mice were infected with CHIKV. Sera were taken at different days postinfection and measured for anti-CHIKV Ab levels. Isotype and neutralizing capacity of these Abs were assessed in vitro, and specific linear epitopes were mapped. Viremia in CHIKV-infected μMT mice persisted for more than a year, indicating a direct role for B cells in mediating CHIKV clearance. These animals exhibited a more severe disease than WT mice during the acute phase. Characterization of CHIKV-specific Abs revealed that anti-CHIKV Abs were elicited early and targeted epitopes mainly at the C terminus of the virus E2 glycoprotein. Furthermore, CD4(-/-) mice could still control CHIKV infection despite having lower anti-CHIKV Ab levels with reduced neutralizing capacity. Lastly, pre-existing natural Abs in the sera of normal WT mice recognized CHIKV and were able to partially inhibit CHIKV. Taken together, natural and CHIKV infection-induced specific Abs are essential for controlling CHIKV infections.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23670192      PMCID: PMC3677171          DOI: 10.4049/jimmunol.1300304

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  44 in total

1.  Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages.

Authors:  Karine Labadie; Thibaut Larcher; Christophe Joubert; Abdelkrim Mannioui; Benoit Delache; Patricia Brochard; Lydie Guigand; Laurence Dubreil; Pierre Lebon; Bernard Verrier; Xavier de Lamballerie; Andreas Suhrbier; Yan Cherel; Roger Le Grand; Pierre Roques
Journal:  J Clin Invest       Date:  2010-02-22       Impact factor: 14.808

2.  I-TASSER: a unified platform for automated protein structure and function prediction.

Authors:  Ambrish Roy; Alper Kucukural; Yang Zhang
Journal:  Nat Protoc       Date:  2010-03-25       Impact factor: 13.491

3.  Viperin restricts chikungunya virus replication and pathology.

Authors:  Terk-Shin Teng; Suan-Sin Foo; Diane Simamarta; Fok-Moon Lum; Teck-Hui Teo; Aleksei Lulla; Nicholas K W Yeo; Esther G L Koh; Angela Chow; Yee-Sin Leo; Andres Merits; Keh-Chuang Chin; Lisa F P Ng
Journal:  J Clin Invest       Date:  2012-11-19       Impact factor: 14.808

4.  Type I IFN controls chikungunya virus via its action on nonhematopoietic cells.

Authors:  Clémentine Schilte; Thérèse Couderc; Fabrice Chretien; Marion Sourisseau; Nicolas Gangneux; Florence Guivel-Benhassine; Anton Kraxner; Jürg Tschopp; Stephen Higgs; Alain Michault; Fernando Arenzana-Seisdedos; Marco Colonna; Lucie Peduto; Olivier Schwartz; Marc Lecuit; Matthew L Albert
Journal:  J Exp Med       Date:  2010-02-01       Impact factor: 14.307

Review 5.  Chikungunya: a potentially emerging epidemic?

Authors:  Michelle M Thiboutot; Senthil Kannan; Omkar U Kawalekar; Devon J Shedlock; Amir S Khan; Gopalsamy Sarangan; Padma Srikanth; David B Weiner; Karuppiah Muthumani
Journal:  PLoS Negl Trop Dis       Date:  2010-04-27

6.  A pathogenic role for CD4+ T cells during Chikungunya virus infection in mice.

Authors:  Teck-Hui Teo; Fok-Moon Lum; Carla Claser; Valeria Lulla; Aleksei Lulla; Andres Merits; Laurent Rénia; Lisa F P Ng
Journal:  J Immunol       Date:  2012-12-03       Impact factor: 5.422

Review 7.  Chikungunya: a bending reality.

Authors:  Zhisheng Her; Yiu-Wing Kam; Raymond T P Lin; Lisa F P Ng
Journal:  Microbes Infect       Date:  2009-09-10       Impact factor: 2.700

8.  B cell intrinsic MyD88 signals drive IFN-gamma production from T cells and control switching to IgG2c.

Authors:  Tom A Barr; Sheila Brown; Pietro Mastroeni; David Gray
Journal:  J Immunol       Date:  2009-06-19       Impact factor: 5.422

9.  Destructive arthritis in a patient with chikungunya virus infection with persistent specific IgM antibodies.

Authors:  Denis Malvy; Khaled Ezzedine; Maria Mamani-Matsuda; Brigitte Autran; Hugues Tolou; Marie-Catherine Receveur; Thierry Pistone; Jérome Rambert; Daniel Moynet; Djavad Mossalayi
Journal:  BMC Infect Dis       Date:  2009-12-10       Impact factor: 3.090

10.  Prophylaxis and therapy for Chikungunya virus infection.

Authors:  Thérèse Couderc; Nassirah Khandoudi; Marc Grandadam; Catherine Visse; Nicolas Gangneux; Sébastien Bagot; Jean-François Prost; Marc Lecuit
Journal:  J Infect Dis       Date:  2009-08-15       Impact factor: 5.226

View more
  76 in total

1.  Immunopathogenesis of alphaviruses.

Authors:  Victoria K Baxter; Mark T Heise
Journal:  Adv Virus Res       Date:  2020-07-08       Impact factor: 9.937

2.  Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus.

Authors:  Scott A Smith; Laurie A Silva; Julie M Fox; Andrew I Flyak; Nurgun Kose; Gopal Sapparapu; Solomiia Khomandiak; Solomiia Khomadiak; Alison W Ashbrook; Kristen M Kahle; Rachel H Fong; Sherri Swayne; Benjamin J Doranz; Charles E McGee; Mark T Heise; Pankaj Pal; James D Brien; S Kyle Austin; Michael S Diamond; Terence S Dermody; James E Crowe
Journal:  Cell Host Microbe       Date:  2015-07-08       Impact factor: 21.023

3.  A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.

Authors:  Juan García-Arriaza; Victoria Cepeda; David Hallengärd; Carlos Óscar S Sorzano; Beate Mareike Kümmerer; Peter Liljeström; Mariano Esteban
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

4.  Monoclonal Antibodies as Prophylactic and Therapeutic Agents Against Chikungunya Virus.

Authors:  April M Clayton
Journal:  J Infect Dis       Date:  2016-12-15       Impact factor: 5.226

Review 5.  Animal Models of Chikungunya Virus Infection and Disease.

Authors:  Nicole N Haese; Rebecca M Broeckel; David W Hawman; Mark T Heise; Thomas E Morrison; Daniel N Streblow
Journal:  J Infect Dis       Date:  2016-12-15       Impact factor: 5.226

Review 6.  Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies.

Authors:  Laurie A Silva; Terence S Dermody
Journal:  J Clin Invest       Date:  2017-03-01       Impact factor: 14.808

7.  CD8+ T cells control Ross River virus infection in musculoskeletal tissues of infected mice.

Authors:  Kristina S Burrack; Stephanie A Montgomery; Dirk Homann; Thomas E Morrison
Journal:  J Immunol       Date:  2014-12-08       Impact factor: 5.422

8.  γδ T Cells Play a Protective Role in Chikungunya Virus-Induced Disease.

Authors:  Kristin M Long; Martin T Ferris; Alan C Whitmore; Stephanie A Montgomery; Lance R Thurlow; Charles E McGee; Carlos A Rodriguez; Jean K Lim; Mark T Heise
Journal:  J Virol       Date:  2015-10-21       Impact factor: 5.103

9.  Pathogenic Chikungunya Virus Evades B Cell Responses to Establish Persistence.

Authors:  David W Hawman; Julie M Fox; Alison W Ashbrook; Nicholas A May; Kristin M S Schroeder; Raul M Torres; James E Crowe; Terence S Dermody; Michael S Diamond; Thomas E Morrison
Journal:  Cell Rep       Date:  2016-07-21       Impact factor: 9.423

10.  Protective and Pathogenic Responses to Chikungunya Virus Infection.

Authors:  Kristin M Long; Mark T Heise
Journal:  Curr Trop Med Rep       Date:  2015-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.